Literature DB >> 9723643

Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina.

A Gaspardone1, F Crea, F Versaci, F Tomai, A Pellegrino, L Chiariello, P A Gioffrè.   

Abstract

Plasma levels of C-reactive protein were measured 72 hours after successful coronary artery stenting in 76 patients with stable angina pectoris. At 12-month follow-up, the cumulative event rate was higher in patients with abnormal levels of C-reactive protein than that observed in patients with normal C-reactive protein who were event free.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9723643     DOI： 10.1016/s0002-9149(98)00370-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  23 in total

1.  Interleukin 18 in acute myocardial infarction.

Authors:  Y Seta; T Kanda; T Tanaka; M Arai; K Sekiguchi; T Yokoyama; M Kurimoto; J Tamura; M Kurabayashi
Journal:  Heart       Date:  2000-12       Impact factor: 5.994

2.  Exercise induced myocardial ischaemia does not cause increase in C-reactive protein concentration.

Authors:  A Gaspardone; M Perino; A S Ghini; F Tomai; F Versaci; I Proietti; F Crea
Journal:  Heart       Date:  2000-12       Impact factor: 5.994

3.  Osteoprotegerin is not associated with angiographic coronary calcification.

Authors:  Prospero B Gogo; David J Schneider; Edward F Terrien; Burton E Sobel; Harold L Dauerman
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

4.  Role of pre-procedural C-reactive protein level in the prediction of major adverse cardiac events in patients undergoing percutaneous coronary intervention: a meta-analysisof longitudinal studies.

Authors:  Singh-Baniya Bibek; Yong Xie; Jia-Jia Gao; Zhi Wang; Jing-Feng Wang; Deng-Feng Geng
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

5.  Changes in anti-heat shock protein 27 antibody and C-reactive protein levels following cardiac surgery and their association with cardiac function in patients with cardiovascular disease.

Authors:  Amir Ali Rahsepar; Asadollah Mirzaee; Fatemeh Moodi; Mohsen Moohebati; Shima Tavallaie; Fatemeh Khorashadizadeh; Ali Eshraghi; Maryam-Sadat Alavi; Laya Zarrabi; Mostafa Sajjadian; Maral Amini; Roshanak Khojasteh; Roghayeh Paydar; Somayeh Mousavi; Majid Ghayour-Mobarhan; Gordon A Ferns
Journal:  Cell Stress Chaperones       Date:  2012-07-30       Impact factor: 3.667

6.  Prediction of cardiovascular events by inflammatory markers in patients undergoing carotid stenting.

Authors:  Francesco Versaci; Bernhard Reimers; Francesco Prati; Achille Gaspardone; Costantino Del Giudice; Andrea Pacchioni; Alessandro Mauriello; Claudio Cortese; Paolo Nardi; Anna De Fazio; Giovanni Alfonso Chiariello; Igino Proietti; Luigi Chiariello
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

Review 7.  Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis.

Authors:  Pramod Kuchulakanti; Ron Waksman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention.

Authors:  Nihat Ozer; Burak Tangurek; Fatih Firat; Songul Ozer; Zeynep Tartan; Recep Ozturk; Batuhan Ozay; Figen Ciloglu; Hale Yilmaz; Nese Cam
Journal:  Heart Vessels       Date:  2008-04-04       Impact factor: 2.037

9.  Baseline inflammation is not predictive of periprocedural troponin elevation after elective percutaneous coronary intervention.

Authors:  Olivier Gach; Olivier Louis; Jean Paul Chapelle; Sophie Vanbelle; Luc A Pierard; Victor Legrand
Journal:  Heart Vessels       Date:  2009-07-22       Impact factor: 2.037

10.  Increase in interleukin-6 in the first hour after coronary stenting: an early marker of the inflammatory response.

Authors:  Atul Aggarwal; David J Schneider; Edward F Terrien; Kristin E Gilbert; Harold L Dauerman
Journal:  J Thromb Thrombolysis       Date:  2003-02       Impact factor: 2.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.